Financing translation: Analysis of the NCATS rare-diseases portfolio
The portfolio of the National Center for Advancing Translational Sciences (NCATS) rare-diseases therapeutic development program comprises 28 research projects initiated at the preclinical stage. Historical data reveal substantially lower costs and higher success rates but longer preclinical timeline...
Main Authors: | Fagnan, David E., Yang, N. Nora, McKew, John C., Lo, Andrew W |
---|---|
Other Authors: | Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory |
Format: | Article |
Language: | en_US |
Published: |
American Association for the Advancement of Science (AAAS)
2015
|
Online Access: | http://hdl.handle.net/1721.1/99456 https://orcid.org/0000-0003-2944-7773 |
Similar Items
-
Financing drug discovery for orphan diseases
by: Gromatzky, Austin A., et al.
Published: (2014) -
QuaNCAT: Quantitating proteome dynamics in primary cells
by: Howden, A, et al.
Published: (2013) -
QuaNCAT: quantitating proteome dynamics in primary cells.
by: Howden, A, et al.
Published: (2013) -
Analytics for financing drug development
by: Fagnan, David Erik
Published: (2015) -
Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences
by: Abouarab, Bechara, et al.
Published: (2023)